Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Nanobiotix. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Nanobiotix's earnings available for a low price, and how does
this compare to other companies in the same industry?
Nanobiotix is not considered high growth as it is expected to be loss making for the next 1-3 years.
Nanobiotix's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Nanobiotix's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
Mr. Laurent Lévy, Ph.D. serves as the President of the Executive Board and Chief Executive Officer of Nanobiotix SA at Valbiotis SAS. Mr. Lévy co-founded Nanobiotix SA in 2003. Mr. Lévy has a thorough understanding of the technical, scientific and marketing of nanotechnologies, since he has been working with these tools for almost 10 years. His leading work at the frontier of biotechnologies and nanotechnologies has permited to develop a large number of applications. He has also worked for 3 years in business development with major health care industry players (Aventis, Guerbet, Rhodia, L'Oreal) and biotechnologies startup. He is the author of 25 international publications and communications and of a patent in this area. He serves as Chairman of the Supervisory Board at Valbiotis SA. He carried out his postdoctoral work at the Institute for Laser Photonics and Biophotonics at the State University of New York (SUNY), Buffalo. Mr. Lévy studied PhD in Physical Chemistry specialized in nanomaterials from Pierre et Marie Curie University-CEA (Atomic Energy Agency, Saclay, France) and holds a DEA in condensed matter at the UPVI-ESPCI (Paris, France).
Laurent's compensation has increased whilst company is loss making.
Laurent's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure
Average tenure and age of the
management team in years:
The tenure for the Nanobiotix management team is about average.
Chief Financial & Administrative Officer and Member of the Executive Board
Chief Medical Officer
Chief Business Officer & Member of Executive Board
Co-Founder and Member of Scientific Board
Chief Operating Officer
Director of Investor Relations
Head of Communication & Public Affairs Department
Vice President of Corporate Development
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The tenure for the Nanobiotix board of directors is about average.
Nanobiotix SA, a late stage clinical company, develops and sells nanomedicine for the treatment of cancer. It develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. The company’s products include NBTXR3, a preclinical research program for cancer immunotherapies. Nanobiotix SA was incorporated in 2003 and is headquartered in Paris, France.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.